Sept. 19, 2015
Below are current clinical trials.1 studies in Neuromyelitis optica
(open studies only).
Filter this list of studies by location, status and more.
A Double Blind Trial to Evaluate the Safety and Efficacy of Eculizumab in Relapsing NMO Patients (PREVENT Study)
Study type: Interventional What is this?
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase: III What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study
The primary objective of the study is to assess the efficacy and safety of eculizumab treatment as compared to placebo in relapsing NMO patients using a time to first relapse study design.
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
Print study details
- Rochester, Minnesota: 14-001640
NCT ID: NCT01892345
Sponsor Protocol Number: ECU-NMO-301
- Pereira W, et al. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review. Journal of the Neurological Sciences. 2015;355:7.
- NINDS neuromyelitis optica information page. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/neuromyelitis_optica/neuromyelitis_optica.htm. Accessed Sept. 3, 2015.
- Wingerchuk DM, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177.
- Symptoms and diagnosis of NMO. National Multiple Sclerosis Society. http://www.nationalmssociety.org/What-is-MS/Related-Conditions/Neuromyelitis-Optica-(NMO)/Symptoms-and-Diagnosis. Accessed Sept. 3, 2015.
- Riggin EA. Enterprise Performance Management system. Mayo Clinic, Rochester, Minn. July 22, 2015.
- Network of pediatric MS centers. National Multiple Sclerosis Society. http://www.nationalmssociety.org/What-is-MS/Who-Gets-MS/Pediatric-MS/Care-for-Pediatric-MS-(Centers-of-Excellence). Accessed Sept. 3, 2015.
- Glisson CC. Neuromyelitis optica (NMO) and NMO spectrum disorders. http://www.uptodate.com/home. Accessed Sept. 3, 2015.
- Matiello M, et al. Neuromyelitis optica. Current Opinion in Neurology. 2007;20:255.
- Riggin EA. Enterprise Performance Management system. Mayo Clinic, Rochester, Minn. Sept. 3, 2015.
- Wingerchuk DM, et al. The spectrum of neuromyelitis optica. Lancet Neurology. 2007;6:805.